Analysis for Schwab U.S. Large-Cap Value ETF
Analysis summary
Schwab U.S. Large-Cap Value ETF (SCHV) currently has a total score of 66 points, placing it in the strong range. The score is made up of Performance (52), Stability (89) and Trend (66). The profile is clearly uneven: Stability stands out while Performance is more neutral.
Performance scores 52 points (neutral). Key strength: 1Y return at 17.2 %. Weaker metric: 10Y return at 143.7 %. This points to a sharper upswing more recently.
Stability scores 89 points (very strong). Key strength: volatility (365d, annualized) at 15.5 %. Even the weakest metric remains solid in absolute terms: CAGR/drawdown ratio at 0.25. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 66 points (strong). Key strength: trend strength at 0.91. Main drag: Price is about 4.9 % above SMA50.
Overall, the profile has a clear strength in Stability, while Performance is the main limiter. On a metric level, volatility (365d, annualized) stands out, while 10Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Schwab U.S. Large-Cap Value ETF fit best in FoxScore?
- Schwab U.S. Large-Cap Value ETF fits a more defensive investor type in FoxScore: stability is the strongest part of the profile. That points to comparatively smaller drawdowns and calmer swings versus the universe — but prices can still fall.
- How meaningful is the available history for Schwab U.S. Large-Cap Value ETF?
- Schwab U.S. Large-Cap Value ETF currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.